MediRox AB (MediRox) is engaged in the production of instruments, diagnostic reagents and quality control material for visco elasticity and coagulation measurements. It develops and markets the ReoRox rheometers utilising its patented FOR technology. Its products portfolio includes coagulation multi-controls, coagulation reagents and instruments for advanced coagulation analysis. The company is headquartered in Nykoping, Sweden.

In 2008, the company launched ReoRox G2 for hemostasis evaluation. Using ReoRox G2, the visocity and elasticity measurements in coagulation samples can be monitored at the same time. It measures 3- times higher elasticity compared to traditional ROTEG and TEG analysers.The company reported revenues of (Swedish Krona) SEK 16.34 million during the fiscal year ended December 2008, an increase of 6.71% over 2007. The operating profit of the company was SEK 0.29 million during the fiscal year 2008, an increase of 148.70% over 2007. The net profit of the company was SEK 0.18 million during the fiscal year 2008, an increase of 69.90% over 2007.

Street: 
Studsvik GPL 13
City: 
Nykoping
Postcode: 
611 82
Federal State : 
Sweden
WebSite: 
www.medirox.se
Fax: 
46-155-263011

Company Index Score

Current Index Score Historical Index Score
  • MediRox AB currently scores 50 % in the index.
  • MediRox AB is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • MediRox AB is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets